Compliance / Healthcare compliance
Where compliance is most of the risk, not paperwork around it.
In life sciences, the compliance step isn't a formality. It's the actual product. Every engagement is screened for the constraints specific to this industry before an expert is ever put in front of a client.
What this includes
Sunshine Act / Open Payments
Reporting obligations are tracked and handled on the expert's behalf where applicable, not left for them to figure out.
Off-label guardrails
Topic scoping keeps conversations with practicing clinicians inside appropriate discussion boundaries.
Code alignment
Engagement structure is built with PhRMA and AdvaMed code principles in mind.
In-house, not outside counsel
This is reviewed by our own compliance team, every time, as standard practice.
Questions people ask
Who reports Sunshine Act payments: us or the expert?
Where the engagement structure requires it, we handle the reporting logistics so the expert isn't left to track it themselves.
What stops a call from drifting into off-label territory?
Topics are scoped in advance and experts are briefed on the boundary before the call starts. It's a stated constraint, not an assumption everyone's expected to know.
Does this apply to medtech and diagnostics too, or just pharma?
The same discipline applies across pharma, medtech, and diagnostics engagements. The specific rules (e.g., AdvaMed vs. PhRMA code) differ, but the screening step doesn't.
Where this applies